These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: [New substances and dosages for thrombolysis in acute myocardial infarct]. Author: Zeymer U, Neuhaus KL. Journal: Z Kardiol; 1993; 82 Suppl 2():137-41. PubMed ID: 8328192. Abstract: The aim of thrombolytic therapy in acute myocardial infarction is the early, complete and sustained restoration of bloodflow in the infarct-related artery. In a randomized trial in 421 patients with acute myocardial infarction front-loaded rt-PA (100 mg in 90 min) showed a significantly higher 90-min patency (84.4%) in comparison with APSAC (70.3%). In-hospital mortality was significantly lower after rt-PA (2.4%) versus 8.1% after APSAC. While a single bolus injection of rt-PA produced lower patency and higher reocclusion rates, double bolus injections showed more promising results (90 min patency > 70%). A new recombinant plasminogen activator BM 06.022 (r-PA) with a longer half life can be given as a single bolus injection. In a dose-finding study r-PA produced rapid thrombolysis with a 90-min patency of 66% (10 MU) and 76% (15 MU). There was no excess in re-occlusions or bleeding complications. Although these results are quite promising, the search for the ideal thrombolytic strategy is still ongoing.[Abstract] [Full Text] [Related] [New Search]